Phase 2 Study in Systemic Lupus Erythematosus (SLE)

Double-blind, randomized, placebo-controlled study

Primary Endpoint: Musculoskeletal Pain assessed by NRS-Pain Score

Secondary Endpoints: Overall disease activity using SLE Responder Index; Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA); SLE Disease Activity Index (SLEDAI); British Isles Lupus Activity Group (BILAG)

Key study inclusion criteria:*

• Fulfill updated ACR 1997 Revised Criteria for the Classification of Systemic Lupus Erythematous
• 18 years of age and less than 70 at the time consent is signed
• Seven-day average of maximum of daily pain NRS scores ≥4 out of 10 during screening with continued reporting of pain NRS scores on at least 67% of days during the screening period.

*There are additional criteria you must meet to be able to participate in this study.

For Complete Study Details, Please View the Study Listing on clinicaltrials.gov: ClinicalTrials.gov Identifier: NCT03093402

Medical professionals may email us at SLEphysicians@corbuspharma.com for more information about study participation.

Patients, caregivers or patient advocates looking for additional information may email us at SLEpatients@corbuspharma.com.

For any other inquiries, please see our Contact Us page.